Royalty Pharma PLC reports results for the quarter ended December 31 - Earnings Summary

Royalty Pharma

11/02/2025 14:31

* Royalty Pharma PLC  RPRX.OQ  reported quarterly adjusted
earnings of $1.15​​ per share for the quarter ended December 31,
identical to the same quarter last year.  The mean expectation
of seven analysts for the quarter was for earnings of $1.05 per
share. Wall Street expected results to range from 65 cents
to $1.24 per share.
    * Revenue fell 0.3% to $594.00 million from a year ago;
analysts
expected $678.89 million. 
    * Royalty Pharma PLC's reported EPS for the quarter was 35
cents​.
    * The company reported quarterly net income of $208 million.
    * Royalty Pharma PLC shares had risen by 24.3% this quarter.

FORECAST CHANGES
    * The mean earnings estimate of analysts had risen by
about 6.9%
in the last three months.​ 
    * In the last 30 days, there have been no negative revisions
of
earnings estimates

RECOMMENDATIONS
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 5 "strong buy" or "buy," 2
"hold" and no "sell" or "strong sell." 
    * The average consensus recommendation for the
pharmaceuticals
peer group is also "buy"

Wall Street's median 12-month price target for Royalty Pharma
PLC is $40.50 
This summary was machine generated from LSEG data February 11 at
02:31 p.m. UTC. ​All figures in US dollars unless otherwise
stated. (For questions concerning the data in this report,
contact Estimates.Support@lseg.com. For any other questions or
feedback, contact RefinitivNewsSupport@thomsonreuters.com) QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Dec. 31 2024      1.05           1.15           Beat
 Sep. 30 2024      0.93           1.01           Beat
 Jun. 30 2024      0.97           0.96           Missed
 Mar. 31 2024      0.98           0.98           Met